AbbVie is past the worst of Humira biosimilar erosion with Skyrizi and Rinvoq combined trajectory above $24B by 2027. Cerevel and ImmunoGen acquisitions add neuroscience and oncology. Aesthetics business stable. Capital allocation disciplined with steady dividend growth. Re-rating possible as biosimilar cliff fades from narrative.
Thesis reviewed May 29, 2026
AbbVie Inc. is headquartered in United States, which is currently showing moderate signals.
πΊπΈUnited States59NEUTRALView United States risk detail βπPharma0NEUTRAL| Ticker | Company | Score | Gap | Signal Ξ | Action |
|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | 50 | +8% | β0% | NEUTRAL |
| LLY | Eli Lilly and Company | 50 | +24% | β0% | EARLY |
| TAK | Takeda Pharmaceutical Company Limited | 50 | +10% | β0% | NEUTRAL |
| REGN | Regeneron Pharmaceuticals Inc. | 50 | -16% | β0% | AVOID |
| SNY | Sanofi | 50 | +14% | β0% | EARLY |
| RDY | Dr Reddy's Laboratories Ltd | 50 | +7% | β0% | NEUTRAL |
| NVO | Novo Nordisk A/S | 50 | +15% | β0% | EARLY |
Investors who hold ABBV may also have indirect exposure through these country funds.
Skyrizi/Rinvoq combined sales exceed Humira peak
Cerevel emraclidine Phase 3 data positive
Estimates Β· Yahoo Finance Β· Not audited figures
| Politician | Party | Type | Amount | Trade Date | Return |
|---|---|---|---|---|---|
| Alan Armstrong | Buy | $15kβ$50k | Mar 27, 26 | ||
| Josh GottheimerNJ | Buy | $1kβ$15k | May 5, 26 | ||
| Donald J. TrumpFL | R | Buy | $50kβ$50k | Mar 11, 26 | +4.4% |
| Julie JohnsonTX | D | Buy | $1kβ$15k | Dec 18, 25 | +2.1% |
| Julia LetlowLA | R | Buy | $1kβ$15k | Apr 28, 25 | +0.2% |
| Julia LetlowLA | R | Buy | $1kβ$15k | Jan 24, 25 | +0.2% |
| Julia LetlowLA | R | Buy | $1kβ$15k | Dec 8, 25 | +0.2% |
| Julia LetlowLA | R | Buy | $1kβ$15k | Oct 23, 24 | +0.2% |
| John Boozman | Sell | $1kβ$15k | Aug 11, 25 | +2.1% | |
| John Boozman | Sell | $1kβ$15k | Aug 22, 25 | +2.1% | |
| Marjorie Taylor Mrs GreeneGA | R | Buy | $1kβ$15k | Nov 20, 24 | +33.4% |
| John JamesMI | R | Buy | $1kβ$15k | Sep 4, 24 | +19.4% |
| John JamesMI | R | Buy | $1kβ$15k | Nov 10, 23 | +17.6% |
| Kathy ManningNC | Buy | $1kβ$15k | Jul 2, 24 | +19.1% |